An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Frequency Therapeutics (FREQ) announced CEO David L. Lucchino's participation in two investor conferences. The Cowen 42nd Annual Health Care Conference will feature a corporate panel discussion on March 7, 2022, from 2:10 p.m. to 3:10 p.m. EST. The Oppenheimer 32nd Annual Healthcare Conference will include a company overview presentation on March 16, 2022, from 3:20 p.m. to 3:50 p.m. EST. Investors can access live webcasts on the company's website, with replays available post-event. Frequency focuses on regenerative medicine, particularly for hearing loss and multiple sclerosis.
Positive
None.
Negative
None.
LEXINGTON, Mass.--(BUSINESS WIRE)--
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person’s innate regenerative potential to restore function, today announced that Chief Executive Officer David L. Lucchino will participate in two upcoming investor conferences:
Cowen 42nd Annual Health Care Conference: Corporate Panel Discussion - Auditory and Ophthalmology, March 7, 2022, 2:10 p.m. to 3:10 p.m. EST
Oppenheimer 32nd Annual Healthcare Conference: Company Overview Presentation, Wednesday, March 16, 2022, 3:20 p.m. to 3:50 p.m. EST
A live webcast of both the panel and presentation can be accessed on the investors section of Frequency’s website, investors.frequencytx.com. A replay of each will be posted on the Frequency website following the events.
About Frequency Therapeutics
Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore function – first in hearing loss and then in multiple sclerosis (MS) – by developing therapeutics that activate a person’s innate regenerative potential within the body through the activation of progenitor cells to restore lost function. Frequency’s hearing research focuses on cochlear restoration and auditory repair, and its lead asset, FX-322, is a small-molecule product candidate that is the first to show statistically significant and clinically meaningful hearing improvements in clinical trials for SNHL. Frequency is also following early restorative signals in MS to develop medicines with the same underlying regenerative science being brought to hearing loss.
Headquartered in Lexington, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, the Scripps Research Institute and Cambridge Enterprises Limited. For more information, visit www.frequencytx.com and follow Frequency on Twitter @Frequencytx.
When is the Cowen 42nd Annual Health Care Conference for Frequency Therapeutics?
The Cowen 42nd Annual Health Care Conference is on March 7, 2022, from 2:10 p.m. to 3:10 p.m. EST.
What will Frequency Therapeutics present at the Oppenheimer 32nd Annual Healthcare Conference?
Frequency Therapeutics will provide a company overview presentation at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, from 3:20 p.m. to 3:50 p.m. EST.
How can I watch the Frequency Therapeutics investor conference presentations?
Live webcasts of both presentations can be accessed on Frequency Therapeutics' investors website, with replays available after the events.
What is Frequency Therapeutics focused on in regenerative medicine?
Frequency Therapeutics is focused on developing therapeutics for hearing loss and multiple sclerosis by activating the body's innate regenerative potential.
What is FX-322 by Frequency Therapeutics?
FX-322 is Frequency Therapeutics' lead asset, a small-molecule product candidate aimed at restoring hearing function.
